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ABSTRACT - The spinocerebellar ataxias (SCAs) are a clinically and genetically heterogeneous group of late 
onset neurodegenerative disorders. To date, seven different genes causing autosomal dominant SCA have been 
mapped: SCA1, SCA2, Machado-Joseph disease (MJD)/SCA3, SCA4, SCA5, SCA7 and dentatorubropallidoluysian 
atrophy (DRPLA). Expansions of an unstable trinucleotide CAG repeat cause three of these disorders: SCA1, 
MJD/SCA3 and DRPLA. We studied one Brazilian family segregating an autosomal dominant type of SCA. A 
total of ten individuals were examined and tested for the presence of the SCA1, MJD and DRPLA mutations. 
Three individuals, one male and two females, were considered affected based on neurological examination; 
ages at onset were: 32, 36 and 41 years. The first complaint in all three patients was gait ataxia which progressed 
slowly over the years. Six individuals showed one allele containing an expanded CAG repeat in the SCA1 gene. 
The mean size of the expanded allele was 48.2 CAG units. Instability of the expanded CAG tract was seen in the 
two transmissions that were observed in this family. In both occasions there was a contraction of the CAG tract. 
Our study demonstrates that SCA1 occurs in the Brazilian population. In addition, our results stress the importance 
of molecular studies in the confirmation of diagnosis and for pre-symptomatic testing in SCAs. 
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Características clínicas e moleculares de uma família brasileira com ataxia espinocerebelar tipo 1 
RESUMO - As ataxias espinocerebelares (AECs) fazem parte de um grupo de doenças neurodegenerativas que 
apresentam grande heterogeneidade clínica e genética. Existem até o momento sete genes mapeados responsáveis 
pelas AECs de transmissão autossômica dominante: SCA1, SCA2, doença de Machado-Joseph (DA/7) ou SCA3, 
SCA4, SCA5, SCA7 e atrofia dentatorubropalidoluisiana (ADRPL). Uma expansão de um trínucletídeo CAG 
foi identificada como a mutação responsável na SCA], DMJ e ADRPL. Estudamos uma família brasileira com 
uma forma autossômica dominante de AEC. Dez indivíduos foram examinados e amostras de sangue foram 
colhidas para os estudos moleculares das mutações causadoras da SCA1, DMJ e ADRPL. Três membros da 
família foram considerados clinicamente afetados, um indivíduo do sexo masculino e dois do sexo feminino. A 
idade de início dos sintomas foi 32, 36 e 41 anos. Ataxia da marcha, lentamente progressiva, foi a primeira 
manifestação da doença nos três pacientes. Em seis indivíduos os estudos moleculares mostraram um alelo com 
expansão da sequência CAG contida no gene SCA1. O tamanho médio do alelo CAG expandido foi 48,2 unidades. 
O alelo SCA 1 expandido apresentou instabilidade nas duas trasmissões observadas, nas quais ocorreram contrações 
de uma e de seis unidades CAG. O nosso estudo mostra que a SCA1 ocorre na população brasileira. Além disso, 
os nossos resultados reforçam a importância dos estudos moleculares na confirmação diagnostica e no diagnóstico 
pré-sintomático de pacientes com AEC. 
PALAVRAS-CHAVE: doença neurodegnerativa, ataxia espinocerebelar, expansão de trínucleotídeo. 
The spinocerebellar ataxias (SCAs) are a heterogeneous group of adult onset neurodegenerative 
disorders characterized clinically by progressive cerebellar ataxia with variable associated features 
including ophthalmoplegia, dysarthria, dysphagia, pyramidal and extrapyramidal signs. Genetically, 
these disorders can be divided into: autosomal recessive, autosomal dominant, and isolated cases. 
To date, seven different loci causing autosomal dominant SCA are mapped: the SCA1 locus on 
chromosome 6 p l 2 , w , the SCA2 locus on chromosome 12q7-1 6-2 1, the Machado- Joseph disease (MJD)/ 
SCA3 locus on chromosome 14q3 0-3 3-3 6-3 l t, the SCA4 locus on chromosome 16q6, the SCA5 locus on 
the centromeric region of chromosome I I 2 5 , the SCA7 locus on chromosome 3p 2 , 9 and the 
dentatorubropallidoluysian atrophy {DRPLA) locus on chromosome 12p 1 5. However, there are 
families that do not map to any of these locations 1 7 , 3 7. The mutations causing three of these disorders, 
SCA I22, MJD/SCA33M]9 andDRPLAls, have been identified. In all three instances affected individuals 
have an expansion of a trinucleotide CAG repeat in the coding region of the disease genes. 
The identification of these three mutations responsible for SCA allows us to recognize families 
that segregate SCA 1, MJD or DRPLA, thus providing means for accurate classification and diagnosis 
of these disorders. We undertook this study in order to determine whether a mutation in one of the 
SCA genes identified (SCA1, MJD and DRPLA) was responsible for the disease in a Brazilian 
family with autosomal dominant SCA. 
SUBJECTS 
A total of ten individuals were examined and bloods were collected for molecular studies. All individuals 
in this family were enrolled in a genetic counseling program prior to the study and received supportive counseling 
throughout the clinical evaluation and molecular testing. 
METHODS 
DNA isolation 
Genomic DNA was isolated from peripheral blood leukocytes using standard manual techniques 2". 
PCR analysis 
The published primer sequences: Repl and Rep2 2 2 , MJD52 and M J D 2 5 ' \ and B37 CAG repeat primer 
sequences 1 ' were used for detection of the SCA1, MJD, and DRPLA mutations, respectively. Polymerase chain 
reaction (PCR) was carried out in a total volume of 12.5ul, with lOOng of genomic DNA; luM of each primer; 
200^M of dGTP, dCTP, dTTP and dATP; 1 unit of Taq polymerase and 2% formamide. Samples were processed 
through 30 to 32 cycles of denaturation, annealing, and elongation at different temperatures, as described 
previously 1 2 . PCR products were separated in 6% polyacrylamide gels. Gels were transferred into Hybond N+ 
nylon membranes and hybridized with a a - 3 2 P 3'-end labelled (CAG) 1 5 probe. Allele sizes were determined by 
comparing migration relative to an M13 sequencing ladder. Patients previously identified with the SCA1, MJD 
and DRPLA mutations were used as positive controls in all analyses. 
As previously reported for the SCA I gene, normal alleles have a size range of 6 to 39 CAG repeats, while 
affected alleles have 40 to 81 CAG repeats 4- 8 1 3 2 0 - 2 3 . The normal DRPLA allele ranges from 8 to 25 CAGs, while 
in affected DRPLA alleles 54 to 68 CAGs are found 1 5. In normal individuals the MJD gene contains 12 to 37 
CAG repeats, while in affected patients the repeat number ranges from 62 to 8 4 3 1 9 . 
RESULTS 
This Brazilian family is probably of Italian origin; however Portuguese background cannot 
be completely excluded. Of the ten family members examined there were three clinically affected 
individuals, one male and two females. The Figure shows the reduced pedigree of the family and the 
Table summarizes the demographic and molecular information obtained in the study. 
Individual II-1 began to develop gait ataxia at age 41, neurological examination after 5 years 
of disease onset showed moderate gait ataxia, incoordination in upper limbs, globally increased 
deep tendon reflexes and pyramidal signs. A CT scan at the time of examination revealed cerebellar 
atrophy. Individual II-4 began to have gait ataxia at age 32. The disease has progressed slowly and 
after 4 years of disease evolution he presented mild gait ataxia, incoordination in upper limbs and 
increased knee jerk. A CT scan was considered normal. Individual II-5 started symptoms about one 
year before examination at age 36 and showed only mild gait ataxia. Other clinical findings including 
cognitive impairment, optic atrophy, ophthalmoplegia, dysphagia, dystonia and Parkinsonian features 
were not seen in this family. All remaining individuals examined were clinically normal. 
Six individuals had an abnormal CAG repeat in the SCA1 gene (Figure), three males and 
three females. The number of repeats in the expanded allele varied from 44 to 51 CAG units, with a 
mean of 48.2. Mild instability of the CAG tract was seen in the two transmissions that could be 
documented in this family. In both occasions there was a contraction of the CAG tract, of one and six 
CAG units. By contrast, the normal alleles were transmitted in a mendelian fashion and varied from 
30 to 33 CAG repeats (Figure). 
The appearance of the normal and the expanded CAG repeats in the SCA1 gene varied markedly. 
All the normal alleles had a single strong band distinctively seen in the autoradiographs, whereas the 
expanded alleles showed several bands (Figure). 
The ten individuals genotyped in this family had CAG repeats of normal size in the M/D and 
DRPLA genes (data not shown). 
DISCUSSION 
The classification of the autosomal dominant SCAs has been difficult due to variability and 
overlapping in clinical characteristics and pathological presentation5. It is not uncommon to find 
affected individuals, in the same family, with a wide variety of symptoms 1 0. It is now generally 
accepted that the controversies involving diagnosis and classification of this group of disorders will 
only be solved when the molecular aspects are clarified26. With the cloning of the SCA J, MJD and 
DRPLA genes and the characterization of the respective mutations an accurate diagnosis can now be 
performed, even in small families or single affected individuals. This will result in a better estimate 
of the prevalence of these disorders, as well as provide more detailed clinical, pathological and 
molecular information that will improve our understanding of these group of diseases. 
We 3 2 and others2 4 have determined the frequency of the three different SCAs for which direct 
molecular diagnosis is available: SCAI, MJD and DRPLA. Families of different geographic and 
ethnic origins have been reported with the SCAI mutation; however, SCAI seems to occur more 
frequently in certain ethnic groups such as Italians and Eastern (EuropeansRanum et al. 2 4, Silveira et 
al. 3 2 , and Lopes-Cendes unpublished results]. In Southern Italy a cluster of SCAI families has been 
described sharing the same haplotype for markers closely linked to the SCAI locus, which suggests 
a common origin of these families 1 2. Therefore, it is not surprising to find SCAI families in Brazil 
particularly in regions of strong Italian immigration. The family described in this paper is most 
likely of Italian background. 
Clinical variability is usually present in SCAI, even within the same family. There has been 
no description of any clinical feature that is specific for SCAI patients 8 , 2 0 , 3 4. Symptoms usually begin 
in the third and fourth decade of life and are characterized by gait ataxia, dysarthria, and 
ophthalmoplegia". Limb ataxia is typically less severe than gait ataxia. In the early stages, eye 
movements appear to be full and the saccadic velocities are relatively preserved34. The disorder 
gradually progresses and patients become bedridden after 10 to 20 years of disease evolution. In the 
later stages of the disease, distal areflexia occurs, and dysphagia develops leading to frequent choking 
spells and aspiration pneumonia. Some degree of increased tone as well as dystonic movement may 
occur late in the course of the disease. Dementia has not been observed in genetically proven SCAI 
families; although mild cognitive decline may occur in the advanced stages of the disease3 4. Infrequent 
signs include optic atrophy and Parkinsonian features8 , 2 0. One of the largest SCAI families studied, 
the Schut kindred, shows remarkable heterogeneity in disease presentation, with cases starting in the 
first or second decades of life and progressing rapidly, as well as patients with onset after the fourth 
decade presenting a mild disease 2 9. The Brazilian SCAI family reported here is relatively small and 
does not permit extensive clinical correlations; however it seems that the disease presentation has 
been very similar in the three clinically affected individuals, and with no specific associated features 
such as: slow eye movements, extrapyramidal features, peripheral signs, retinal degeneration and 
myoclonus, which are more frequently found in SCA2, MJD, SCA4, SCA7 and DRPLA patients, 
respectively 2 , 6 , 1 5 1 6 1 8 , 2 5 , 2 6 . Small families with patients presenting a short evolution of the disease, such as 
the Brazilian SCAI pedigree, represent a very difficult problem for the clinical differential diagnosis. 
We believe that diagnostic questions in SCA patients can only be solved with molecular testing. 
The observation that in one single family, the disease has a tendency for a progressive earlier 
onset with increased severity in younger generations has intrigued researchers in the field of SCAs 
for a long time. This phenomenon, called anticipation, is observed in other neurodegenerative 
disorders, such as: Huntington disease, Kennedy disease, MJD and DRPLA 3 5. All of which are 
caused by an expansion of a trinucleotide CAG. It has been observed that translation of the mutant 
protein actually occurs and that the CAG stretch codes for a polyglutamine tract at the protein 
level 1 1 , 3 1 . These observations suggest a toxic gain of function by the proteins containing an expanded 
glutamine tract 1 1 , 2 7. In addition, the observed inverse correlation between the repeat size and age at 
onset of the disease and the tendency of an overall increase in the CAG repeat size in successive 
generations 1 3 , 2 3, indicate that this toxic effect is proportional to the length of the polyglutamine tract. 
Therefore, offering a possible molecular explanation for the phenomenon of anticipation observed 
in these neurodegenerative disorders. 
The molecular characteristics of the expanded CAG repeat found in this family are similar to 
those reported in other SCAI families 8 , 1 3 , 2 0 , 2 2 . We observed mild instability during transmission of 
the expanded CAG tract, suggesting gametic mosaicism. In addition, the observation of multiple 
bands for the expanded allele, that were seen in the autoradiographs, indicates the presence of somatic 
mosaicism, with different cells containing different lengths of the CAG repeat. 
In SCAI families an inverse correlation between the size of the CAG repeat and the age at 
onset of the disease has been observed 1 3 , 2 0 , 2 2 , 2 3 ; however this correlation is not perfect, only about 
66% of variability in age at onset can be attributed to the length of the CAG repeat in these SCAI 
patients. This suggests that there are factors other than the repeat size involved in the determination of 
the disease phenotype. Therefore, the size of the CAG repeat is not a good predictor of age at onset in 
SCAI. Although the CAG tract has a tendency for expansion in successive generations1 3 , 2 3, anticipation 
cannot be always observed, since contractions, as seen in the Brazilian SCAI family, also occur. 
Confirmation or exclusion of diagnosis can be accomplished in almost all pre-symptomatic 
or suspected cases of SCA1, specially if affected family members are also tested. The availability of 
such highly sensitive and specific test for a late onset disorder has raised several questions about 
ethic and legal aspects of molecular testing in at risk individuals1. This emphasizes the importance 
of a multidiciplinary supportive counseling program that should be available for all individuals 
undergoing this type of molecular testing. 
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